MARKET

DNLI

DNLI

Denali Therapeut
NASDAQ
16.51
+0.10
+0.61%
After Hours: 16.69 +0.18 +1.09% 18:51 12/31 EST
OPEN
16.42
PREV CLOSE
16.41
HIGH
16.67
LOW
16.28
VOLUME
1.16M
TURNOVER
--
52 WEEK HIGH
24.35
52 WEEK LOW
10.57
MARKET CAP
2.57B
P/E (TTM)
-5.6716
1D
5D
1M
3M
1Y
5Y
1D
Denali Therapeutics announces publication of Phase 1/2 study of DNL310
TipRanks · 12/30/2025 13:15
Denali Therapeutics' Tividenofusp Alfa Demonstrates Biomarker And Clinical Improvements In Hunter Syndrome, Published In NEJM As FDA Review Nears April 2026 Decision
Benzinga · 12/30/2025 13:07
Denali Shares Phase 1/2 Results for Rare Disease Treatment as FDA Reviews Accelerated Approval
Benzinga · 12/30/2025 13:02
Denali Therapeutics Reports Positive Phase 1/2 Results for Tividenofusp Alfa in Hunter Syndrome
Reuters · 12/30/2025 13:00
3 Biotech Stocks With Major 2026 Catalysts
NASDAQ · 12/29/2025 14:13
Weekly Report: what happened at DNLI last week (1222-1226)?
Weekly Report · 12/29/2025 09:16
Denali Therapeutics (DNLI): Revisiting Valuation After Secondary Offering and FDA Priority Review Voucher Progress
Simply Wall St · 12/25/2025 12:26
Does Denali’s $200M Equity Raise And FDA Talks Change The Bull Case For DNLI?
Simply Wall St · 12/23/2025 18:15
More
About DNLI
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.

Webull offers Denali Therapeutics Inc stock information, including NASDAQ: DNLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNLI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DNLI stock methods without spending real money on the virtual paper trading platform.